<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03505762</url>
  </required_header>
  <id_info>
    <org_study_id>CCCWFU 98317</org_study_id>
    <secondary_id>NCI-2018-00585</secondary_id>
    <secondary_id>CCCWFU 98317</secondary_id>
    <secondary_id>P30CA012197</secondary_id>
    <nct_id>NCT03505762</nct_id>
  </id_info>
  <brief_title>Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment</brief_title>
  <official_title>A Randomized Phase II Pilot of Tailored Prednisone Reduction Versus Usual Care for the Treatment of Hyperglycemia During R-CHOP Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well tailored prednisone reduction works in preventing
      hyperglycemia in participants with B-cell non-Hodgkin lymphoma receiving combination
      chemotherapy treatment. Drugs used in chemotherapy, such as rituximab, cyclophosphamide,
      doxorubicin hydrochloride, vincristine sulfate and prednisone, work in different ways to stop
      the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
      stopping them from spreading. Reductions in prednisone dose may lower blood sugar levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare the cumulative incidence of hyperglycemia after 3 cycles of treatment between
      standard or tailored rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine
      sulfate and prednisone (R-CHOP) chemotherapy.

      SECONDARY OBJECTIVES:

      I. To compare the cumulative incidence of hyperglycemia after 6 cycles of treatment and at 6
      months post-treatment between standard or tailored R-CHOP chemotherapy.

      II. To compare response rates after 6 cycles of treatment as measured by Cheson's criteria
      between standard or tailored R-CHOP chemotherapy.

      III. To compare cumulative rates of grade III or higher adverse events using Common
      Terminology Criteria for Adverse Events (CTCAE) criteria between standard or tailored R-CHOP
      chemotherapy from cycle 1 through cycle 6.

      IV. To compare severity of prednisone related adverse events using the Patient Reported
      Outcome (PRO)-CTCAE form between standard or tailored R-CHOP chemotherapy from cycle 1
      through cycle 6.

      V. To compare health related quality of life (HRQOL) between standard or tailored R-CHOP
      chemotherapy at baseline, cycle 4 day 1 and after cycle 6.

      EXPLORATORY OBJECTIVES:

      I. To evaluate the alternative glucose measures of fasting blood glucose (FBG), hemoglobin
      A1c (HbA1c), fasting insulin and fructosamine to estimate hyperglycemia.

      II. To compare health related quality of life (HRQOL) in those with and without hyperglycemia
      after 3 cycles, 6 cycles, and 6 months post R-CHOP chemotherapy.

      III. To compare glycemic variability between the standard and tailored prednisone arms at day
      1 of each cycle IV. To determine the ability of patients in the standard or tailored
      prednisone R-CHOP groups to complete all six cycles of chemotherapy.

      OUTLINE: Participants are randomized to 1 of 2 arms.

      ARM I: Participants receive rituximab intravenously (IV), vincristine sulfate IV, doxorubicin
      hydrochloride IV, and cyclophosphamide IV on day 1. Participants also receive tailored
      prednisone dose orally (PO) once daily (QD) on days 1-5. Treatment repeats every 21 days for
      up to 6 courses in the absence of disease progression or unacceptable toxicity.

      ARM II: Participants receive rituximab, vincristine sulfate doxorubicin hydrochloride, and
      cyclophosphamide as in Arm I. Participants also receive usual care prednisone dose PO QD on
      days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, participants are followed up for 30 days, then up to 6
      months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of hyperglycemia of standard or tailored rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP)</measure>
    <time_frame>After course 3 (63 days)</time_frame>
    <description>Will use the Kaplan Meier method to estimate the cumulative incidence of hyperglycemia, and the log-rank test to compare hyperglycemia incidence by arm after 3 cycles of R-CHOP chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of hyperglycemia of standard or tailored R-CHOP</measure>
    <time_frame>Baseline up to 6 months</time_frame>
    <description>Will use the Kaplan Meier method to estimate the cumulative incidence of hyperglycemia, and the log-rank test to compare hyperglycemia incidence by arm after 6 cycles and after 6 months of R-CHOP chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates of standard or tailored R-CHOP as measured by Cheson's criteria</measure>
    <time_frame>After of course 6 (126 days)</time_frame>
    <description>Will use a Fisher's exact test to compare response rates after 6 cycles of R-CHOP by arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of grade III or higher adverse events using Common Terminology Criteria for Adverse Events (CTCAE) criteria from standard or tailored R-CHOP</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will compare the rates of the incidence of grade III and higher events by arm of R-CHOP for each cycle using Fisher's exact tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of prednisone related adverse events using the Patient Reported Outcome (PRO)-CTCAE</measure>
    <time_frame>Up to course 6 (126 days)</time_frame>
    <description>Will compare the scoring of PRO-CTCAE assessments by arm of R-CHOP using two group t-tests at each time point of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life (HRQOL) scores</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluated using the Functional Assessment of Cancer Therapy (FACT)-Lymphoma, FACT Gynecologic Oncology Group-Neurotoxicity additional concerns and Patient-Reported Outcomes Measurement Information System 29. Will compare the HRQOL measures between arms receiving R-CHOP chemotherapy using two group t-tests at each time point of interest.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fasting blood glucose (FBG) levels</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will examine glucose variability over time in FBG using linear mixed effects models to model between and with-person variation in glucose.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hemoglobin A1C (HbA1c) levels</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will examine glucose variability over time in HbA1c using linear mixed effects models to model between and with-person variation in glucose.</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting insulin</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will examine glucose variability over time in fasting insulin using linear mixed effects models to model between and with-person variation in glucose.</description>
  </other_outcome>
  <other_outcome>
    <measure>Fructosamine levels</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will examine glucose variability over time in fructosamine using linear mixed effects models to model between and with-person variation in glucose.</description>
  </other_outcome>
  <other_outcome>
    <measure>HRQOL scores in those with and without hyperglycemia</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will compare quality of life between the those who are hyperglycemic and those that are not at cycle 3, cycle 6, and 12 months using a mixed model analysis covariance (ANCOVA) with adjustment for baseline quality of life.</description>
  </other_outcome>
  <other_outcome>
    <measure>Glycemic variability</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>To compare glycemic variability between the arms, will model variability using mixed effect models of FBG and random blood glucose over time, allowing for differing within-person variance by arm as well as fitting a model with pooled variance and any characteristics that differ between the groups. Will use likelihood ratio tests to compare if there is greater variability in the tailored versus standard arms by comparing the pooled variance model to the model that allows the within-person variation to vary by arm.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of patients in the standard and tailored prednisone R-CHOP arms who complete all six cycles of chemotherapy</measure>
    <time_frame>End of course 6 (126 days)</time_frame>
    <description>Will compare the proportion of participants by arm using Fisher's exact test.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>B-Cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I (tailored prednisone dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive rituximab IV, vincristine sulfate IV, doxorubicin hydrochloride IV, and cyclophosphamide IV on day 1. Participants also receive tailored prednisone dose PO QD on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (usual care prednisone dose)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive rituximab, vincristine sulfate doxorubicin hydrochloride, and cyclophosphamide as in Arm I. Participants also receive usual care prednisone dose PO QD on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (tailored prednisone dose)</arm_group_label>
    <arm_group_label>Arm II (usual care prednisone dose)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (tailored prednisone dose)</arm_group_label>
    <arm_group_label>Arm II (usual care prednisone dose)</arm_group_label>
    <other_name>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)</other_name>
    <other_name>ADM</other_name>
    <other_name>Adriacin</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin Hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>ADRIAMYCIN, HYDROCHLORIDE</other_name>
    <other_name>Adriamycine</other_name>
    <other_name>Adriblastina</other_name>
    <other_name>Adriblastine</other_name>
    <other_name>Adrimedac</other_name>
    <other_name>Chloridrato de Doxorrubicina</other_name>
    <other_name>DOX</other_name>
    <other_name>DOXO-CELL</other_name>
    <other_name>Doxolem</other_name>
    <other_name>Doxorubicin.HCl</other_name>
    <other_name>Doxorubin</other_name>
    <other_name>Farmiblastina</other_name>
    <other_name>FI 106</other_name>
    <other_name>FI-106</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (tailored prednisone dose)</arm_group_label>
    <arm_group_label>Arm II (usual care prednisone dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (tailored prednisone dose)</arm_group_label>
    <arm_group_label>Arm II (usual care prednisone dose)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary correlative</description>
    <arm_group_label>Arm I (tailored prednisone dose)</arm_group_label>
    <arm_group_label>Arm II (usual care prednisone dose)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (tailored prednisone dose)</arm_group_label>
    <arm_group_label>Arm II (usual care prednisone dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (tailored prednisone dose)</arm_group_label>
    <arm_group_label>Arm II (usual care prednisone dose)</arm_group_label>
    <other_name>ABP 798</other_name>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>CT-P10</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab Biosimilar ABP 798</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar CT-P10</other_name>
    <other_name>Rituximab Biosimilar GB241</other_name>
    <other_name>Rituximab Biosimilar IBI301</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>Rituximab Biosimilar SAIT101</other_name>
    <other_name>RTXM83</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (tailored prednisone dose)</arm_group_label>
    <arm_group_label>Arm II (usual care prednisone dose)</arm_group_label>
    <other_name>Kyocristine</other_name>
    <other_name>Leurocristine sulfate</other_name>
    <other_name>Leurocristine, sulfate</other_name>
    <other_name>Oncovin</other_name>
    <other_name>Vincasar</other_name>
    <other_name>Vincosid</other_name>
    <other_name>Vincrex</other_name>
    <other_name>Vincristine, sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of B cell non-Hodgkin lymphoma confirmed by World Health Organization (WHO)
             criteria

          -  Planned treatment with R-CHOP chemotherapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3

          -  Life expectancy of greater than 3 months with chemotherapy

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             the duration of study participation; should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her treating physician
             immediately

          -  Ability to understand and the willingness to sign an Institutional Review Board
             (IRB)-approved informed consent document (either directly or via a legally authorized
             representative)

        Exclusion Criteria:

          -  Uncontrolled human immunodeficiency virus (HIV), CD4 count &lt; 50

          -  Diagnosis of primary central nervous system (CNS) lymphoma

          -  Unable to receive R-CHOP chemotherapy

          -  History of severe (i.e. anaphylactic) allergic reactions attributed to compounds of
             similar chemical or biologic composition to glucocorticoids and other component of R-

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection not controlled with antibiotics, symptomatic congestive heart failure,
             unstable angina pectoris, cardiac arrhythmia that cannot be rate controlled with
             medications, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if
             the mother is treated with these agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zanetta Lamar</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zanetta S. Lamar</last_name>
      <phone>336-716-5847</phone>
      <email>zlamar@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Zanetta S. Lamar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2018</study_first_submitted>
  <study_first_submitted_qc>April 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Cortisone acetate</mesh_term>
    <mesh_term>Cortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

